top of page
IMG_20200327_105405.jpg

Dr. Rakesh Kundu

Assistant Professor

Email: rakesh.kundu@visva-bharati.ac.in

About the Faculty

Dr. Rakesh Kundu joined the department in the year 2012. He has obtained his masters degree from Banaras Hindu University (2000) and his doctoral degree from Visva-Bharati (2009). Before joining the department he worked as a Assistant professor (Temporary) at the Guru Ghasidas University, Bilaspur (2009-2010) and as a project assistant (Level-I) at the CSIR-North East Institute of Science & Technology, Jorhat, Assam (2010-2011). His research area of interest includes Fetuin-A mediated insulin secretory defects; ß-Cell inflammation, Islet Biology; CD36-TLR4, Lipid accumulation; Nrf2-Keap1 signaling.

Awards and Professional Recognitions

  • ICMR-DHR International Fellowship for Young Biomedical Scientists (May 2024-Jan 2025), ICMR, Govt. of India, 2024 for high end research training in the Centre for Biomolecular Interactions Bremen (CBIB), University of Bremen, Germany

  • SERB International Research Experience (SIRE) visiting scientist award, SERB, Govt. of India, 2022

  • INSA Visiting Scientist, Indian National Science Academy, 2021-22

  • ISE Travel Fellowship Award from International Society of Endocrinology (ISE) to attend ICE-SEMDSA 2018 conference at Cape Town, South Africa, 2018.

  • Early Career Research (ECR) Award, SERB, Govt. of India, 2017 | UGC-BSR Research Start-up-Grant, UGC, Govt. of India, 2014

Life Memberships

  • International society of endocrinology (ISENDO)

  • Society of Biological Chemists

  • Indian Science Congress Association (ISCA)

  • ​Society for Reproductive Biology and Comparative Endocrinology (SRBCE)

Current Research Activities

  • Our present study focuses on the role of CD36 on palmitate-fetuin-A mediated lipid accumulation in beta-cell, its inflammation, and insulin secretory defects. We use high fat-fed (HFD) animal model (C57BL6/J mice) and in vitro cell culture (MIN6) to observe physiological effects and pathway studies respectively [Nature Medicine 2012; JBC 2013; BBRC 2017; MCE 2021; JCP 2021, JCS 2021, BBA 2024]. 

  • Anti-inflammatory effects of DPP-4 inhibitors [BBRC 2023, BBA 2024]. 3. Nrf2-Keap1 signaling in lung cancer. Screening of Nrf2 inhibitors to address cancer drug resistance using cell culture and in vivo models. [TIV 2020; ABB 2020, TIV 2024] 

Titles         

Year

Duration

Sanctioned Amount
(In Lakhs)

PI/Co-PI

Status

Elucidating the role of CD36 and its association with Fetuin-A-TLR4 pathway in promoting pancreatic beta cell inflammation, lipid accumulation and insulin secretory defects in diabetic mice models.

2023

3

_

PI: Dr. Rakesh Kundu

Ongoing

To investigate the role of Fetuin-A in lipotoxicity induced beta-cell dysfunction and inflammatory injury to the pancreatic islets.

2018

3

_

PI: Dr. Rakesh Kundu

Completed

Understanding the role of Nrf2-Keap1 pathway in developing drug resistance in lung cancer cells.

2014

2

_

PI: Dr. Rakesh Kundu

Completed

bottom of page